Nelson Leung, MD, Mayo Clinic, Rochester, MN, discusses measurable residual disease (MRD) negativity in AL amyloidosis patients undergoing kidney transplantation. Dr Leung discusses a paper he co-authored investigating the impact of MRD negativity with Mass-Fix as a surrogate on the outcomes of AL amyloidosis patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).